Clearside Biomedical
CLSDCLSD · Stock Price
Historical price data
Overview
Clearside Biomedical is revolutionizing ocular therapeutics through its proprietary suprachoroidal space (SCS) delivery platform. The company's mission is to preserve and improve vision by enabling targeted, in-office administration of therapies directly to the choroid, retina, and macula. Its strategy is validated by the commercial approval of XIPERE® and is centered on advancing its lead internal asset, CLS-AX for wet AMD, into Phase 3, while leveraging its platform through strategic collaborations with other biopharma companies to expand the pipeline across multiple retinal indications.
Technology Platform
Proprietary suprachoroidal space (SCS) injection platform utilizing the SCS Microinjector® for targeted, compartmentalized delivery of therapies to the back of the eye.
Pipeline
13| Drug | Indication | Stage | Watch |
|---|---|---|---|
| 4 mg CLS-TA Suprachoriodal Injection | Uveitis | Phase 3 | |
| suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or Av... | Macular Edema | Phase 3 | |
| 4mg CLS-TA Suprachoriodal Injection + Sham Procedure | Uveitis | Phase 3 | |
| suprachoroidal CLS-TA + suprachoroidal sham + IVT aflibercep... | Macular Edema | Phase 3 | |
| IVT aflibercept + Sham SC + SC CLS-TA | Diabetic Macular Edema | Phase 2 |
Opportunities
Risk Factors
Competitive Landscape
Clearside is the first-mover and leader in suprachoroidal delivery, competing against established intravitreal anti-VEGF biologics and newer long-acting therapies. Its primary differentiation is the targeted SCS route of administration, which aims for improved therapeutic index. Platform competition exists but is far less mature.